Gender differences in the efficacy of pioglitazone treatment in nonalcoholic fatty liver disease patients with abnormal glucose metabolism

Table 3 Interaction between changes of LFC and gender in the PGZ + LSI group compared with the LSI group in different models

	Absolute changes of LFC (%)	Men	Women	Interaction test P value
Model 1	β (95%CI)	9.79 (0.37, 19.21)	− 8.26 (− 17.18, − 0.65)	0.003
Model 1	P value*	0.046	0.025	0.003
Model 2	β (95%CI)	8.42 (− 1.40, 18.23)	− 8.19 (− 16.64, − 0.27)	0.011
Model 2	P value*	0.099	0.033	0.011
Model 3	β (95%CI)	5.25 (− 3.25, 18.76)	− 7.75 (− 12.32, − 0.13)	0.039
Model 3	P value*	0.464	0.045	0.039
Model 4	β (95%CI)	6.09 (− 3.02, 15.20)	− 5.25 (− 13.38, 2.88)	0.024
Model 4	P value*	0.193	0.210	0.024
Model 5	β (95%CI)	5.86 (− 3.24, 14.97)	− 4.78 (− 13.43, 3.88)	0.059
Model 5	P value*	0.211	0.283	0.059
Model 6	β (95%CI)	6.98 (− 6.59, 14.54)	− 3.33 (− 11.09, 4.44)	0.291
Model 6	P value*	0.801	0.405	0.291

Data are shown as means (95% confidence interval). Absolute changes of LFC (%), difference of the absolute changes of LFC for men or women between the PGZ + LSI and LSI groups. Model 1: not adjusted; model 2: adjusted for age, smoking, drinking, baseline BMI, change of BMI, and treatment adherence; model 3: adjusted for baseline LFC and variables in model 2; model 4: adjusted for glucose metabolism and variables in model 2; model 5: adjusted for change of HOMA-IR and variables in model 2; model 6: adjusted for baseline LFC, glucose metabolism, change of HOMA-IR, and variables in model 2. Interaction test P value was assessed by Wald’s test
LFC liver fat content
*P value calculated by linear regression model, difference between the PGZ + LSI group and the LSI group

ISSN: 2042-6410